Close Menu

This story has been corrected to remove a reference to sensitivity across multiple tumor types.

NEW YORK – Guardant Health said on Thursday that the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) has approved its Guardant Reveal liquid biopsy test for the detection and monitoring of minimal residual disease in patients with early-stage cancer, initially colorectal cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.